This medication is used to manage Diabetes Mellitus, supporting individuals with Type 1, Type 2, and sometimes gestational diabetes. It is used in clinical settings that involve the management of chronic hyperglycemia, thereby addressing the symptoms related to systemic imbalance that characterize the condition.

The therapeutic benefit is often applied in clinical settings where the management of poorly controlled Type 2 Diabetes is required when oral treatments alone are insufficient. Insugen 30/70 is used for managing symptoms related to daily blood sugar by assisting with the management of fluctuating daily glucose patterns. This dual support contributes to easing the symptom load during symptomatic periods.

“This medication is commonly used for patients whose management requires dual symptomatic support.”

The management of blood sugar is relevant for easing the risk of future, progressive conditions linked to organ-specific functional stress, which are common long-term complications. When used appropriately to manage blood sugar levels, the treatment supports general well-being and may assist with long-term patient health during periods of heightened symptoms.

---

Quick Fact: Support for Fluctuating Blood Sugar Patterns

The medication is commonly used to support the management of unstable daily glucose patterns, which often involve both fasting and post-meal high blood sugar, providing supportive relief when symptoms interfere with routine activities.

Insugen 30/70 is a premixed insulin product containing 30% soluble (short-acting) human insulin and 70% Isophane (intermediate-acting) insulin. It is prescribed for the management of Type 1 and Type 2 diabetes mellitus in both adults and children, working to improve blood sugar control.

Contraindications and When to Exercise Caution

Not everyone can use Insugen 30/70. It is contraindicated and should not be used if you:

• Are currently experiencing an episode of hypoglycemia (very low blood sugar).
• Have a known hypersensitivity or allergy to human insulin or any other ingredient in the product.

Caution and close medical supervision are essential when using this medication if you have certain existing conditions or circumstances. The doctor may need to adjust the dosage.

Condition/Circumstance	Precaution
Kidney or Liver Impairment	Insulin requirements may change.
Heart Problems	Use with caution, especially if taking certain other diabetes medications (TZDs).
Pregnancy or Breastfeeding	Generally considered safe, but dose adjustments and monitoring are necessary.
Illness or Infection	Blood sugar levels may fluctuate, requiring careful management.

Always inform your healthcare provider about all your medical conditions and all other medications you are taking, as drug interactions can increase the risk of hypoglycemia or alter the effectiveness of Insugen 30/70.

Insugen 30/70's official interaction profile is primarily defined by pharmacodynamic relationships that alter the medicine's effect on blood glucose. Co-administration with certain medicinal product categories may formally increase the blood-glucose-lowering effect, which includes substances such as ACE Inhibitors, MAO Inhibitors, Somatostatin Analogs, and various Oral Antidiabetic Agents. Conversely, other agents are officially documented to decrease the blood-glucose-lowering effect, potentially increasing the risk of hyperglycemia. Examples of these substances include Corticosteroids, Diuretics, Sympathomimetic Agents, and Atypical Antipsychotics.

A specific Non-Glycemic Pharmacodynamic Interaction is formally documented with Thiazolidinediones (TZDs), as co-administration may cause or worsen fluid retention and heart failure. Certain other substances, such as Beta-blockers and Clonidine, are documented to have a dual or variable effect on glucose levels while also potentially blunting the physiological signs of hypoglycemia.

Official regulatory constraints include a strict non-mixing rule: Insugen 30/70 must not be mixed with any other insulin product or diluents. Alcohol consumption is noted to have a variable effect, capable of either strengthening or weakening the drug's activity. Furthermore, populations with renal impairment or hepatic impairment are officially noted to have an altered insulin dose requirement.

How Insugen 30/70 Works

Insugen 30/70 introduces active human insulin molecules that are structurally identical to the endogenous peptide. These molecules function as agonists by binding to the Insulin Receptor (IR), a transmembrane glycoprotein located on target cell surfaces, primarily muscle, adipose, and liver tissue.

This binding event triggers the beta-subunit autophosphorylation of the IR, initiating a specific intracellular signaling cascade.

The activated receptor phosphorylates Insulin Receptor Substrates (IRS) proteins, which subsequently engage and activate the Phosphatidylinositol 3-Kinase (PI3K)/Akt pathway. This mechanistic cascade causes the translocation of Glucose Transporter type 4 (GLUT4) containing vesicles to the plasma membrane of muscle and fat cells, facilitating the passive transport of glucose from the extracellular fluid into the cell cytoplasm.

Simultaneously, in hepatic tissue, the drug molecules modulate glucose flux by decreasing the enzymatic activity associated with gluconeogenesis and glycogenolysis, while promoting glycogenesis. The final system-level physiological consequence is enhanced peripheral glucose uptake and reduced endogenous glucose production by the liver.

Insugen 30/70 is a premixed biphasic human insulin containing 30% soluble (short-acting) and 70% isophane (intermediate-acting) insulin, administered via subcutaneous injection. It is essential to follow your healthcare provider’s instructions regarding your specific dose, injection timing, and technique.

Administration and Timing

• Mixing: Before each use, gently roll the pen or vial between your palms and invert it 10 times until the liquid is uniformly cloudy or milky. Do not shake vigorously, as this can cause foaming.
• Timing: The injection is typically given 15 minutes before or within 20 minutes after starting a meal to allow the fast-acting component to work as carbohydrates are absorbed. Do not skip a meal after taking your dose.
• Injection Site: Inject the insulin into the fatty layer just beneath the skin (subcutaneously) in the abdomen, thigh, upper arm, or buttocks. The abdomen generally offers the fastest absorption.
• Rotation: Rotate the injection site within the selected area with each dose to prevent lipodystrophy (skin thickening or pitting). Avoid injecting into bruised, hard, or swollen areas.

Injection Technique

1. Preparation: Wash your hands thoroughly. If using a pen, attach a new, sterile needle and prime the pen (usually 2 units) until a drop of insulin appears at the needle tip to remove air and confirm flow.
2. Injection: Clean the site with an alcohol swab and let it air-dry. Pinch a fold of skin (if advised by your doctor) and insert the needle at a 90-degree angle (or 45 degrees for very thin individuals). Press the plunger/injection button until the dose is delivered.
3. Withdrawal: Count to at least 10 seconds before removing the needle straight out. Do not rub the injection site afterward.

Used needles and syringes must be disposed of immediately in a puncture-resistant sharps container. Never reuse or share needles or insulin pens.

Research Evidence / Overview of Studies for Insugen 30/70

Evidence for Glycemic Control in Diabetes Mellitus

Insugen 30/70 was studied for its role in blood sugar management as part of the overall treatment plan for individuals with Diabetes Mellitus. Research has included foundational Pharmacokinetic/Pharmacodynamic (PK/PD) studies that monitor the product's time-action profile. Furthermore, Randomized Controlled Trials (RCTs) were evaluated in adults with both Type 1 and Type 2 Diabetes, often by comparing the regimen against other insulin types or dosing schedules. These studies typically assessed key long-term biomarkers like Glycosylated Hemoglobin (HbA1c) and daily measurements such as Fasting Plasma Glucose (FPG).

The studies monitored the change in HbA1c levels measured over the observed time intervals in the studied populations. Findings described the patterns observed related to hypoglycemic event frequency when compared to alternative insulin treatments. Research explored whether the biphasic human insulin regimen is comparable to other human premixed insulins. However, the available data are often focused on short-to-intermediate timeframes.

Evidence for Management of Poorly Controlled Type 2 Diabetes

Research has explored the use of Insugen 30/70 in Adults with Type 2 Diabetes whose glucose management had been assessed as sub-optimal despite using other treatments. These studies were frequently Randomized Comparative Pilot Studies, meaning they were smaller in scale and designed to monitor short-term changes when escalating treatment intensity. These studies monitored the change in HbA1c levels and documented the observed patterns in hypoglycemia rates that occurred when patients transitioned to the biphasic regimen. Sample sizes were modest in many of these pilot trials, meaning the results apply only to the populations studied.

Long-Term Studies and Follow-up Duration

Research examined the patterns of glucose control and outcomes over defined time intervals. Many key efficacy trials for Insugen 30/70 have been intermediate in duration, lasting around six to twelve months. There is limited information for long-term outcomes beyond the intermediate trial duration. The patterns of measured changes over many years is not fully established in dedicated prospective studies. As a result, research provides insight into short-term changes but data for long-term maintenance remain insufficient.

What is Still Uncertain About Insugen 30/70 Research

Evidence quality varies across studies, and the results apply only to the populations studied, meaning findings do not determine whether an individual will respond similarly. Follow-up durations were limited in many pivotal trials, meaning the full picture of decades-long use is not fully established. Further research is necessary to explore long-term patterns of metabolic control and to better characterize outcomes in smaller subgroups of patients.

Common questions about Insugen 30/70 (FAQ)

---

Q: What is the difference between Insugen 30/70 and other insulins?

Insugen 30/70 is a mixed insulin formulation. This means it contains 30% soluble insulin (which is fast-acting) and 70% isophane insulin (which is intermediate-acting). This combination provides both a rapid effect to manage blood sugar after a meal and a longer-lasting effect for basal coverage. Other insulins may be solely rapid-acting, short-acting, or long-acting.

---

Q: Do I need to rotate the injection sites when using Insugen 30/70?

Yes, individuals using insulin are consistently advised to rotate injection sites. Injecting in the same area repeatedly can lead to skin changes (such as lipohypertrophy) that can affect how the insulin is absorbed into the body. Rotation helps maintain consistent absorption and healthy skin tissue.

---

Q: Can I use Insugen 30/70 if I am pregnant?

Managing blood sugar levels during pregnancy is essential, and insulin is often the preferred treatment choice. The use of Insugen 30/70 or any specific insulin during pregnancy requires careful consultation and monitoring by a healthcare provider who can weigh the potential benefits and risks.

---

Q: Does Insugen 30/70 cause weight gain?

Insulin therapy, including mixed formulations, may be associated with weight gain in some individuals. This potential effect is influenced by various factors, including diet, activity level, and overall blood sugar control. Any concerns about weight changes should be discussed with a healthcare team.

How to Store and Dispose of Insugen 30/70

The storage and disposal of Insugen 30/70 must strictly adhere to regulatory requirements to maintain product stability and ensure safety.

Official Storage Conditions

Storage Status	Required Temperature Range	Storage Limit
Unopened	Refrigerated: 2 C to 8 C	Until Expiration Date
In-Use	Room Temperature: Up to 30 C	28 days after first use

Unopened product must be stored in the refrigerator and must not be frozen, as freezing renders the insulin unusable. The product must be kept out of the sight and reach of children and protected from light and heat by storing it in its original container.

Disposal

Used needles and syringes must be placed immediately in an approved sharps disposal container. Unused or expired medication must be disposed of according to local community guidelines for pharmaceutical waste, and must not be thrown into household trash or wastewater.